New brain cancer gene therapy RZ-001 shows promise in early trial (opens in new tab)

Rznomics presented Phase 1/2a interim clinical results for RZ-001 (Taspitimagene advec) on June 13 at the Asian Society for Neuro-Oncology annual meeting in Kanazawa, Japan. According to the company, 20 patients have completed screening, and 10 patients were enrolled and treated in the ongoing trial. The interim analysis found no dose-limiting toxicity and no treatment-related […] The post appeared first on <a href="